Tislelizumab (BGB-A317) Clinical Trials
3 recruitingDrug
Phase 22Phase 11
Showing 1–3 of 3 trials
Recruiting
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 1
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Advanced Solid Tumor
Oncomatryx Biopharma S.L.150 enrolled9 locationsNCT05547321
Recruiting
Phase 2
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
MCRC
Beijing Friendship Hospital52 enrolled1 locationNCT06829355